Comparative Pharmacology
Head-to-head clinical analysis: ARISTOGEL versus XENEISOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOGEL versus XENEISOL.
ARISTOGEL vs XENEISOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; binds to androgen receptors, activating gene transcription and increasing protein synthesis.
XENEISOL is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft.
Aristogel is a topical gel containing 1% testosterone. The recommended adult dose is 5 g (50 mg testosterone) applied once daily to clean, dry, intact skin of shoulders, upper arms, and/or abdomen. Apply at approximately the same time each day, preferably in the morning.
10 mg orally once daily, titrated to a maximum of 20 mg daily based on response and tolerability.
None Documented
None Documented
Terminal elimination half-life is 12 hours. Given dosing frequency, steady-state achieved within 2 days; accumulation minimal with standard dosing.
Terminal elimination half-life is 4.5 hours (range 3.5-6 hours) in adults; prolonged to 8-12 hours in hepatic impairment.
Primarily renal (80%) as unchanged drug; 20% fecal via biliary elimination.
Primarily hepatic metabolism followed by renal excretion of metabolites: 70% renal, 20% biliary/fecal, 10% unchanged in urine.
Category C
Category C
Corticosteroid
Corticosteroid